Jan Vilcek relates how his work helped to identify some of the pleiotropic actions of tumor necrosis factor and contributed to the development of infliximab, the first medically useful tumor necrosis factor antagonist.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vilcek, J. My fifty years with interferon. J. Interferon Cytokine Res. 27, 535–542 (2007).
Vilcek, J. An interferon-like substance released from tickborne encephalitis virus-infected chick embryo fibroblast cells. Nature 187, 73–74 (1960).
Vilcek, J. Interferon research BC (before cloning). Curr. Top. Microbiol. Immunol. 316, 9–22 (2007).
Stone-Wolff, D.S. et al. Interrelationships of human interferon-γ with lymphotoxin and monocyte cytotoxin. J. Exp. Med. 159, 828–843 (1984).
Carswell, E.A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666–3670 (1975).
Aggarwal, B.B. et al. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260, 2345–2354 (1985).
Nedwin, G.E. et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res. 13, 6361–6373 (1985).
Beutler, B. et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316, 552–554 (1985).
Tsujimoto, M., Yip, Y.K. & Vilcek, J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. USA 82, 7626–7630 (1985).
Vilcek, J. et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med. 163, 632–643 (1986).
Lin, J.-X. & Vilcek, J. Tumor necrosis factor and interleukin-1 cause a rapid and transient stimulation of c-fos and c-myc mRNA levels in human fibroblasts. J. Biol. Chem. 262, 11908–11911 (1987).
Kohase, M., Henriksen-DeStefano, D., May, L.T., Vilcek, J. & Sehgal, P.B. Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 45, 659–666 (1986).
Reis, L.F.L., Lee, T.H. & Vilcek, J. Tumor necrosis factor acts synergistically with autocrine interferon-β and increases interferon-β mRNA levels in human fibroblasts. J. Biol. Chem. 264, 16351–16354 (1989).
Lee, T.H., Lee, G.W., Ziff, E.B. & Vilcek, J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol. Cell. Biol. 10, 1982–1988 (1990).
Lee, T.H., Wisniewski, H.-G. & Vilcek, J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J. Cell Biol. 116, 545–557 (1992).
Wisniewski, H.-G., Burgess, W.H., Oppenheim, J.D. & Vilcek, J. TSG-6, an arthritis-associated hyaluronan binding protein, forms a stable complex with the serum protein inter-α-inhibitor. Biochemistry 33, 7423–7429 (1994).
Lee, G.W., Lee, T.H. & Vilcek, J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J. Immunol. 150, 1804–1812 (1993).
Wisniewski, H.G. & Vilcek, J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev. 15, 129–146 (2004).
Garlanda, C., Bottazzi, B., Bastone, A. & Mantovani, A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23, 337–366 (2005).
Beutler, B., Milsark, I.W. & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869–871 (1985).
Knight, D.M. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443–1453 (1993).
Siegel, S.A. et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7, 15–25 (1995).
Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681–1690 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vilcek, J. From IFN to TNF: a journey into realms of lore. Nat Immunol 10, 555–557 (2009). https://doi.org/10.1038/ni0609-555
Issue Date:
DOI: https://doi.org/10.1038/ni0609-555
This article is cited by
-
The characteristics of patents impacting availability of biosimilars
Nature Biotechnology (2022)
-
The High Costs of “Free” Drug Samples
Clinical and Translational Gastroenterology (2014)
-
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
American Journal of Gastroenterology (2011)